Last updated on August 24, 2026 · Originally published December 12, 2022
One double bond, moved one position along a ring of carbon atoms. That is the entire difference between delta-9 THC, the famous intoxicant in cannabis, and delta-8 THC, the compound that built a billion-dollar gray market. Move the bond once more and you get delta-10 THC, a molecule that spent decades in obscurity before an industrial accident gave it a second life. Chemists call these near-twins isomers, and understanding them has become essential — not just for pharmacology, but as of this year, for federal law.
What makes two molecules isomers?
Two molecules are isomers when they are built from exactly the same atoms, assembled in different ways. Think of the same set of building bricks put together into two different shapes: identical parts, different objects.
The word can be misleading, because “same atoms” sounds like “basically the same thing.” In biology, it rarely works that way. Enzymes and receptors recognize molecules by their shape, the way a lock recognizes a key. [1] Shift a single chemical bond and a molecule may fit a receptor perfectly, weakly, or not at all — which is why two isomers can produce completely different effects in the body.
How can CBD and THC be so different?
Cannabis offers a famous example. Cannabidiol (CBD) and tetrahydrocannabinol (THC) are isomers: both are built from 21 carbon atoms, 30 hydrogens, and two oxygens. On paper they are the same formula. In the body they are worlds apart.
THC activates the CB1 receptors concentrated in the brain, which is what produces its characteristic intoxicating effects. CBD has little direct agonist activity at CB1 and instead acts through a much broader set of molecular targets, which is why it does not produce the same high. Both molecules are highly lipophilic and can enter the brain. What they do once they arrive is markedly different.
What separates delta-8 THC from delta-9 THC?
THC itself comes in more than one version, and the differences are even subtler than the CBD-THC split. Delta-9 THC is the form cannabis produces in abundance and the one responsible for the plant’s characteristic high. Delta-8 THC is identical except for the position of one double bond in its cyclohexene ring, and it appears in the plant only in traces — so faint that researchers still debate whether the plant truly makes it or whether it forms from delta-9 during drying, extraction, and analysis. [4]
That one repositioned bond changes the molecule’s grip on the CB1 receptor. A 2022 review in the British Journal of Pharmacology concluded that delta-8 behaves much like delta-9 in the body overall, but binds CB1 more weakly — and an early human trial cited in that review found delta-8 to be roughly two-thirds as potent, whether taken orally or intravenously. [3] A separate difference is chemical stability: delta-8 is the more stable of the two isomers, and less prone to the slow oxidation that gradually turns delta-9 THC into cannabinol (CBN) in aging flower and extracts. [4]
Nearly all of the delta-8 sold in stores is not extracted from cannabis at all. It is made by treating hemp-derived CBD with acid, which coaxes the molecule to close a new ring and become THC — mainly delta-9 or delta-8, depending on the catalyst, solvent, temperature and reaction time. Longer or harsher conditions can push delta-9 onward into the more stable delta-8. [2] Telling these nearly identical molecules apart afterward is a genuine analytical challenge, one we have covered in our article on differentiating THC isomers analytically.
Where does delta-10 THC come from?
Delta-10 THC moves the double bond to another position again. It was synthesized and characterized decades ago — a 1984 study by Srebnik, Lander, Breuer and Mechoulam obtained what is now called delta-10 THC, described under the older numbering system as delta-2 THC, through base-catalyzed double-bond isomerization [6] — but it remained largely obscure until an unusual episode introduced it to the commercial cannabis industry.
According to an account published by Extraction Magazine, a California processor working during the 2020 wildfire season encountered unfamiliar crystals in a distillate made from cannabis reportedly exposed to aerially dropped fire retardant. The crystals were misidentified twice before analysis identified them as delta-10 THC, with the contaminant apparently catalyzing the rearrangement during processing. Producers have since developed deliberate conversion methods, so commercial delta-10, like delta-8, is made by chemically rearranging CBD rather than extracted from plants. When a label calls delta-10 a “naturally occurring” cannabinoid, it is worth remembering that its arrival in the modern cannabinoid market is commonly traced to a processing accident.
Its pharmacology remains remarkably uncertain. In a 2023 laboratory study, both the cis and trans forms of delta-10 bound the CB1 receptor far more weakly than delta-9 THC, and neither produced any agonist activity at the concentrations tested — instead, both behaved as antagonists, blocking the receptor rather than switching it on. [5] The authors read that as evidence of a lack of THC-like psychoactivity, a finding not previously reported for any other THC isomer. Whether it predicts how commercial delta-10 products behave in people is an open question: this was cell-based work, not a human trial, and consumer products are often complex mixtures rather than purified isomers.
How does federal law treat THC isomers?
For seven years, all of this chemistry mattered legally because of one molecule. The 2018 Farm Bill defined hemp by its delta-9 THC concentration. Federal crop-testing rules did account for THCA, but the statutory definition still left room for finished products containing intoxicating delta-8 and delta-10 — and courts and federal agencies spent years disagreeing over how converted cannabinoids should be treated.
Congress has now settled the question. Section 781 of Public Law 119-37, signed November 12, 2025, redefines hemp around total THC: delta-9, delta-8, delta-10, and THCA (counted through its conversion factor) are added together against the 0.3% threshold. Finished consumer products face a separate ceiling of 0.4 milligrams per retail container, combining total THC with other cannabinoids determined to have — or marketed as having — THC-like effects. The law also excludes products containing cannabinoids that cannabis cannot naturally produce, and, separately, naturally occurring cannabinoids that were synthesized or manufactured outside the plant. Since nearly all commercial delta-8 and delta-10 comes out of a reactor rather than a plant, that second exclusion reaches most of the market on its own. Products outside the definition lose their federal hemp status and are treated as marijuana under the Controlled Substances Act.
The new definition takes effect on November 12, 2026. As of this writing in late August 2026, the Senate has passed a measure that would postpone most of the changes until December 11, but the House has not agreed and nothing has been signed. Under the Senate text, only the exclusion for cannabinoids that cannabis cannot naturally produce would begin on November 12. Restrictions on naturally occurring cannabinoids manufactured outside the plant — including converted delta-8 — would also wait until December 11. Where converted delta-10 sits is less certain, since that turns on whether cannabis is deemed capable of producing it naturally, and the FDA has yet to publish the lists of cannabinoids the law directed it to compile. Until the proposal becomes law, November 12 remains the operative date.
The shift to total THC also raises the stakes of measurement itself: when every isomer counts toward one number, the question of why two labs can report different THC results for the same sample stops being academic. The same arithmetic is what pulls THCA products into the definition — a change we examine in our article on THCA diamonds.
Why do these small differences matter?
Isomers are a reminder that in chemistry, arrangement is everything. Moving one bond can change how a molecule engages a receptor, how long it survives on a shelf, and how hard it is to measure in a laboratory. For years it could also change a cannabinoid’s federal legal status. The new hemp definition is designed to end that distinction by counting the THC isomers together — proof that sometimes the law answers molecular subtlety by refusing to recognize it.
References:
[1] Chhabra N, Aseri ML, Padmanabhan D. A review of drug isomerism and its significance. International Journal of Applied and Basic Medical Research. 2013;3(1):16–18. doi:10.4103/2229-516X.112233
[2] Marzullo P, Foschi F, Coppini DA, Fanchini F, Magnani L, Rusconi S, Luzzani M, Passarella D. Cannabidiol as the Substrate in Acid-Catalyzed Intramolecular Cyclization. Journal of Natural Products. 2020;83(10):2894–2901. doi:10.1021/acs.jnatprod.0c00436
[3] Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol (Δ8-THC): Comparative pharmacology with Δ9-THC. British Journal of Pharmacology. 2022;179(15):3915–3933. doi:10.1111/bph.15865
[4] Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and Pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. doi:10.3390/molecules29061249
[5] Haghdoost M, Brumar D, Geiling B, Brunstetter M, Bonn-Miller MO. Chemistry, Crystal Structure, and In Vitro Receptor Binding of Δ10-THC Isomers. Cannabis and Cannabinoid Research. 2023;8(S1):S1–S10. doi:10.1089/can.2023.0045
[6] Srebnik M, Lander N, Breuer A, Mechoulam R. Base-catalysed double-bond isomerizations of cannabinoids: structural and stereochemical aspects. Journal of the Chemical Society, Perkin Transactions 1. 1984:2881–2886. doi:10.1039/P19840002881
Updated August 24, 2026: this article was substantially revised and expanded with current research on delta-8 and delta-10 THC and a new section on the federal redefinition of hemp under Public Law 119-37. Reviewed by Nani Frenkel, chief editor.
